Five months after the surprise FDA approval of schizophrenia drug Fanapt (iloperidone), Vanda Pharmaceuticals Inc. nailed down a partner to launch the product. (BioWorld Today)

At last month's BioPharm America conference in San Francisco, biotech experts brushed aside the once-popular business model of using drug delivery or reformulation to provide incremental improvements to existing drugs.

News that MannKind Corp. will not achieve its goal of signing a partnership this year for inhaled insulin product Afresa polarized the company's bullish backers and its bearish detractors. (BioWorld Today)

Inviragen LCC and SingVax Pte Ltd. merged their preclinical vaccine pipelines and closed a $15 million Series A financing to tackle infectious diseases affecting emerging markets. (BioWorld Today)

News that an HIV vaccine actually worked could resurrect AIDSVax, a product most folks left for dead in 2003, while breathing new life into the HIV vaccine field.